OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory UpdateSeptember 30, 2025 7:40 AM EDT | Source: OS TherapiesCompany updates sequence of OST-HER2 regulatory submissions, prioritizing UK MHRA conditional Marketing Authorisation Application (MAA) submission following positive August 2025 Scientific Advice Meeting feedback from UK MHRAIn principle, UK MHRA accepts use of historical control arm to support conditional MAAUK MHRA conditional MAA and US FDA Biologics Licensing ...